Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

Recommendations for Quantitation of the Left Ventricle by Two-Dimensional Echocardiography

Schiller, N. B., Shah, P. M., Crawford, M., DeMaria, A. N., Devereux, R. B., Feigenbaum, H., Gutgesell, H. P., Reichek, N., Sahn, D. J., Schnittger, I., et al. (1989) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(89)80014-8 · Cited by 8,110

Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year

Malmberg, K., Rydén, L., Efendic, S., Herlitz, J., Nicol, P., Waldenstrom, A., Wedel, H., & Welin, L. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00126-k · Cited by 1,560

Clinical Prevention of Sudden Cardiac Death by n-3 Polyunsaturated Fatty Acids and Mechanism of Prevention of Arrhythmias by n-3 Fish Oils

Leaf, A., Kang, J. X., Xiao, Y.-F., & Billman, G. E. (2003) · Circulation · doi:10.1161/01.cir.0000069566.78305.33 · Cited by 605

Glucagon-Like Peptides

Drucker, D. J. (1998) · Diabetes · doi:10.2337/diab.47.2.159 · Cited by 598

Metabolic Modulation of Acute Myocardial Infarction

Díaz, R., Paolasso, E., Piegas, L. S., Tajer, C. D., Moreno, M. G., Corvalán, R., Isea, J., Romero, G., & Collaborative Group (1998) · Circulation · doi:10.1161/01.cir.98.21.2227 · Cited by 517

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.

D'Alessio, D., Kahn, S., Leusner, C. R., & Ensinck, J. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117225 · Cited by 309

Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction

van der Horst, I. C. C., Zijlstra, F., Hof, A. W. J. V. ’., Doggen, C. J. M., de Boer, M., Suryapranata, H., Hoorntje, J. C. A., Dambrink, J. E., Gans, R. O. B., & Bilo, H. J. G. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00830-1 · Cited by 259

Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships

Ritzel, R. A., �rskov, C., Holst, J. J., & Nauck, M. A. (1995) · Diabetologia · doi:10.1007/bf00401846 · Cited by 207

Insulin therapy as an adjunct toreperfusion after acute coronary ischemia

Sack, M. N., & Yellon, D. M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00164-5 · Cited by 105

Glucose-Insulin-Potassium for Acute Myocardial Infarction

Apstein, C. S. (1998) · Circulation · doi:10.1161/01.cir.98.21.2223 · Cited by 95

Effects of glucagon-like peptide 1 on glycemia control and its metabolic consequence after severe thermal injury—studies in an animal model

Shen, C., Fagan, S. P., Fischman, A. J., Carter, E. E., Chai, J., Lu, X.-M., Yu, Y., & Tompkins, R. G. (2011) · Surgery · doi:10.1016/j.surg.2010.11.017 · Cited by 28

Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study

Nogueira, K. C., Furtado, M., Fukui, R. T., Correia, M. R. S., dos Santos, R. F., Andrade, J. L., & da Silva, M. E. R. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-103 · Cited by 28

Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association

Cariou, B. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30006-4 · Cited by 30

Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism

Batran, R. A., Almutairi, M. G., & Ussher, J. R. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.005 · Cited by 28

Therapeutic potential of GLP-1 receptor agonists in diabetes and cardiovascular disease: mechanisms and clinical implications

Zhang, X., Cao, C., Zheng, F., Liu, C., & Tian, X. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07670-9 · Cited by 27

The Antidiabetic Hormone Glucagon-Like Peptide-1 Induces Formation of New Elastic Fibers in Human Cardiac Fibroblasts After Cross-Activation of IGF-IR

Qa’aty, N., Wang, Y., Wang, A., Mao, S., Vincent, M. L., Husain, M., & Hinek, A. (2014) · Endocrinology · doi:10.1210/en.2014-1519 · Cited by 26

Incretin-based therapies: can we achieve glycemic control and cardioprotection?

Angeli, F. S., & Shannon, R. P. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0195 · Cited by 27

Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

Nozue, T., Yamada, M., Tsunoda, T., Katoh, H., Ito, S., Iwaki, T., & Michishita, I. (2015) · Heart and Vessels · doi:10.1007/s00380-015-0734-5 · Cited by 25

Glucagon-Like Peptide 1—A Cardiologic Dimension

Treiman, M., Elvekjær, M., Engstrøm, T., & Jensen, J. S. (2010) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2010.02.012 · Cited by 27

The effect of endogenously released glucose, insulin, glucagon-like peptide 1, ghrelin on cardiac output, heart rate, stroke volume, and blood pressure

Hlebowicz, J., Lindstedt, S., Björgell, O., & Dencker, M. (2011) · Cardiovascular Ultrasound · doi:10.1186/1476-7120-9-43 · Cited by 27

Exenatide: a novel treatment of Type 2 diabetes

Åhrén, B. (2005) · Therapy · doi:10.2217/14750708.2.2.207 · Cited by 26

Glucagon-like peptide-1: physiology and therapeutic potential

Holst, J. J. (2005) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000151395.52819.47 · Cited by 27

Cardiovascular Effects of Incretin-Based Therapies

White, W. B., & Baker, W. L. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-050214-013431 · Cited by 26

The potential role of sphingolipid-mediated cell signaling in the interaction between hyperglycemia, acute myocardial infarction and heart failure

Egom, E. E. A., Mamas, M. A., & Clark, A. L. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.699043 · Cited by 26

Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension

King, N. E., & Brittain, E. L. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12028 · Cited by 28

GLP-1 agonist-based therapies: An emerging new class of antidiabetic drug with potential cardioprotective effects

Sulistio, M. S., Carothers, C., Mangat, M., Lujan, M., OLIVEROS, R. A., & CHILTON, R. J. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0015-9 · Cited by 25

Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study

Nyström, T., Santos‐Pardo, I., Hedberg, F., Wardell, J., Witt, N., Cao, Y., Bojö, L., Nilsson, B., & JENDLE, J. H. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00325 · Cited by 25

Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus

Forst, T., & Pfützner, A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.838559 · Cited by 25

All‐cause mortality and cardiovascular effects associated with the DPP‐IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population

Scheller, N. M., Mogensen, U. M., Andersson, C., Vaag, A. A., & Torp-Pedersen, C. T. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12197 · Cited by 26

Potential Role of Dipeptidyl Peptidase IV in the Pathophysiology of Heart Failure

Salles, T. A., dos SANTOS, L., Baraúna, V. G., & Girardi, A. C. C. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16024226 · Cited by 26

Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1

Clarke, S. J., McCormick, L. M., & Dutka, D. P. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-12 · Cited by 25

Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis

Gargiulo, P., Savarese, G., D’Amore, C., Martino, F. D., Lund, L. H., Marsico, F., Dellegrottaglie, S., Marciano, C., Trimarco, B., & Filardi, P. P. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.09.006 · Cited by 25

Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature

Tibble, C., Cavaiola, T. S., & Henry, R. R. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.13.20 · Cited by 25

Conditioning techniques and ischemic reperfusion injury in relation to on-pump cardiac surgery

Holmberg, F., Ottas, K. A., Andreasen, C., Perko, M. J., Møller, C. H., Engstrøm, T., & Steinbrüchel, D. A. (2014) · Scandinavian Cardiovascular Journal · doi:10.3109/14017431.2014.923930 · Cited by 25

PET of Glucagonlike Peptide Receptor Upregulation After Myocardial Ischemia or Reperfusion Injury

Gao, H., Kiesewetter, D. O., Zhang, X., Huang, X., Guo, N., Lang, L., Hida, N., Wang, H., Wang, H., Cao, F., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.109413 · Cited by 25

Effects of liraglutide on hemodynamic parameters in patients with heart failure

Zhang, J. Y., Wang, X. Y., & Wang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.18570 · Cited by 26

Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2)

Wägner, A. M., Miranda-Calderín, G., Ugarte-Lopetegui, M. A., Marrero-Santiago, H., Suárez-Castellano, L., López-Madrazo, M. J., Alberiche-Ruano, M. P., Ahmed, N. A., Alemán, C., Castellot-Martín, A., et al. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.08.010 · Cited by 25

The use of GLP‐1 receptor agonists in hospitalised patients: An untapped potential

Mustafa, O. G., & Whyte, M. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3191 · Cited by 27

Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis

Cignarelli, A., Genchi, V. A., Le Grazie, G., Caruso, I., Marrano, N., Biondi, G., D’Oria, R., Sorice, G. P., Natalicchio, A., Perrini, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.846903 · Cited by 24

The Place of GLP-1–Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists

Mize, D. L. E., & Salehi, M. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0377-9 · Cited by 24

Divergent Effects of Various Diabetes Drugs on Cardiovascular Prognosis

Bell, D. S. H., Patil, H., & O’Keefe, J. H. (2013) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0671 · Cited by 25

Diabesity in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators

García‐Vega, D., González‐Juanatey, J. R., & Eirás, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147886 · Cited by 26

Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus

Gallwitz, B. (2010) · Drug Safety · doi:10.2165/11319130-000000000-00000 · Cited by 24

Synergistic protection of Danhong Injection (丹红注射液) and ischemic postconditioning on myocardial reperfusion injury in minipigs

Ma, X., Yin, S., Ji-cheng, J., Wu, C., Huang, Y., Shi, D., & Yin, H.-J. (2010) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-010-0567-0 · Cited by 24

Elevated plasma GLP-1 levels and enhanced expression of cardiac GLP-1 receptors as markers of left ventricular systolic dysfunction: a cross-sectional study

Hattori, A., Kawamura, I., Yamada, Y., Kanamori, H., Aoyama, T., Ushikoshi, H., Kawasaki, M., Nishigaki, K., Tamemura, G., & Minatoguchi, S. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003201 · Cited by 24

Postconditioning signalling in the heart: mechanisms and translatability

Bice, J. S., & Baxter, G. F. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12976 · Cited by 24

Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon

Sekar, R., Singh, K., Arokiaraj, A. W. R., & Chow, B. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.05.002 · Cited by 26

Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?

Nauck, M. A., & Smith, U. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.002 · Cited by 24

The Incretin Axis in Cardiovascular Disease

Plutzky, J. (2011) · Circulation · doi:10.1161/circulationaha.111.064139 · Cited by 24

Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus

McCormick, L. M., Heck, P. M., Ring, L. S., Kydd, A. C., Clarke, S. J., Hoole, S. P., & Dutka, D. P. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0259-3 · Cited by 23

Effects of incretin-based therapy in patients with heart failure and myocardial infarction

Mikhail, N. E. (2014) · Endocrine · doi:10.1007/s12020-014-0175-4 · Cited by 22

Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats

Zhou, X., Huang, C.-H., Lao, J. Z., Pocai, A., Forrest, G., Price, O., Roy, S., Kelley, D. E., Sullivan, K. A., & Forrest, M. J. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0194-3 · Cited by 23

Understanding the Cardiovascular Effects of Incretin

Yoon, J. S., & Lee, H. W. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.5.437 · Cited by 23

The intestine responds to heart failure by enhanced mitochondrial fusion through glucagon-like peptide-1 signalling

Naruse, G., Kanamori, H., 吉田明弘, Minatoguchi, S., Kawaguchi, T., Iwasa, M., Yamada, Y., Mikami, A., Kawasaki, M., Nishigaki, K., et al. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz002 · Cited by 23

The Safety and Efficacy of GLP-1 Receptor Agonists in Heart Failure Patients: A Systematic Review and Meta-Analysis

Merza, N., Akram, M., Mengal, A., Rashid, A. M., Mahboob, A., Faryad, M., Fatima, Z., Ahmed, M., & Ansari, S. A. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101602 · Cited by 24

Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?

Giugliano, D., Standl, E., Vilsbøll, T., Betteridge, J. D., Bonadonna, R. C., Campbell, I. W., Schernthaner, G.-H., Staels, B., Trichopoulou, A., & Farinaro, E. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0134-3 · Cited by 23

Cardiovascular Effects of Incretins in Diabetes

Advani, A., Bugyei‐Twum, A., & Connelly, K. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.06.010 · Cited by 25

The role of incretins in cardiovascular control

Mafong, D. D., & Henry, R. R. (2009) · Current Hypertension Reports · doi:10.1007/s11906-009-0005-x · Cited by 23

Exendin-4 ameliorates oxidized-LDL-induced inhibition of macrophage migration in vitro via the NF-κB pathway

Ma, G., Chen, S., Yin, L., Gao, X., & Yao, W. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.128 · Cited by 23

Incretin-based therapies: new treatments for type 2 diabetes in the new millennium

Horowitz, M. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s4975 · Cited by 23

Diabetes Mellitus in Acute Coronary Syndrome

Stampouloglou, P. K., Anastasiou, A., Bletsa, E., Lygkoni, S., Chouzouri, F., Xenou, M., Κατσαρού, Ο., Theofilis, P., Zisimos, K., Tousoulis, D., et al. (2023) · Life · doi:10.3390/life13112226 · Cited by 30

The Impact of Current and Novel anti-diabetic Therapies On Cardiovascular Risk

Ussher, J. R., Sutendra, G., & Jaswal, J. S. (2012) · Future Cardiology · doi:10.2217/fca.12.68 · Cited by 21

Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up

on behalf of the Sitagliptin Registry Kinki Cardiologists’ Study (SIRKAS) Investigators, Nakamura, T., Iwanaga, Y., Miyaji, Y., Nohara, R., Ishimura, T., & Miyazaki, S. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0371-z · Cited by 22

Cardiovascular effects of anti-diabetes drugs

Younk, L. M., Lamos, E. M., & Davis, S. N. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1195368 · Cited by 23

Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip

Luconi, M., Cantini, G., Ceriello, A., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.126 · Cited by 24

Glucagon-Like Peptide Receptor-1 Agonists Used for Medically-Supervised Weight Loss in Patients With Hip and Knee Osteoarthritis: Critical Considerations for the Arthroplasty Surgeon

Heckmann, N. D., Palmer, R. C., Mayfield, C. K., Gucev, G., Lieberman, J. R., & Hong, K. M. (2024) · Arthroplasty Today · doi:10.1016/j.artd.2024.101327 · Cited by 22

Feasibility of Intracoronary GLP-1 Eluting CellBead ™ Infusion in Acute Myocardial Infarction

Houtgraaf, J. H., de Jong, R., Monkhorst, K., Tempel, D., van de Kamp, E. H., den Dekker, W. K., Kazemi, K., Hoefer, I. E., Pasterkamp, G., Lewis, A. L., et al. (2012) · Cell Transplantation · doi:10.3727/096368912x638973 · Cited by 22

Impact of glucagon‐like peptide‐1 on endothelial function

Sjöholm, Å. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01074.x · Cited by 22

Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow

Moberly, S. P., Berwick, Z. C., Owen, M. K., Svendsen, M., Mather, K. J., & Tune, J. D. (2012) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.011288 · Cited by 22

Use Of Incretin-Based Therapy in Hospitalized Patients with Hyperglycemia

Umpierrez, G. E., & Schwartz, S. S. (2014) · Endocrine Practice · doi:10.4158/ep13471.ra · Cited by 22

Stress hyperglycemia in acute myocardial infarction

Koracevic, G. P., Vasiljevic, S., Veličković‐Radovanović, R., Sakač, D., Obradovic, S. D., Damjanović, M., Krstić, N., Zdravkovic, M. D., & Kostić, T. L. (2014) · Vojnosanitetski pregled · doi:10.2298/vsp121103017k · Cited by 22

Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes

Ceriello, A., Novials, A., Ortega, E., Canivell, S., Pujadas, G., Sala, L. L., Bucciarelli, L. G., Rondinelli, M., & Genovese, S. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-97 · Cited by 22

Metabolism of the right ventricle and the response to hypertrophy and failure

Altin, S. E., & Schulze, P. C. (2012) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2012.07.010 · Cited by 22

Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): study protocol for a randomized controlled trial

Scholte, M., Timmers, L., Bernink, F. J. P., Denham, R. N., Beek, A. M., Otto Kamp, B., Diamant, M., Horrevoets, A. J. G., Niessen, H. W. M., Chen, W. J. Y., et al. (2011) · Trials · doi:10.1186/1745-6215-12-240 · Cited by 22

Combined MSC and GLP‐1 Therapy Modulates Collagen Remodeling and Apoptosis following Myocardial Infarction

Wright, E. J., Hodson, N. W., Sherratt, M. J., Kassem, M. S., Lewis, A. L., Wallrapp, C., Malik, N., & Holt, C. M. (2016) · Stem Cells International · doi:10.1155/2016/7357096 · Cited by 21

Exenatide alleviates adriamycin-induced heart dysfunction in mice: Modulation of oxidative stress, apoptosis and inflammation

Fang, J., Tang, Y., Cheng, X. W., Wang, L., Cai, C., Zhang, X., Liu, S., & Li, P. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.03.012 · Cited by 22

Incretin-Based Therapy and Type 2 Diabetes

Hare, K. J., & Knop, F. K. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00015-1 · Cited by 22

Exenatide: A Novel Approach for Treatment of Type 2 Diabetes

Mikhail, N. E. (2006) · Southern Medical Journal · doi:10.1097/01.smj.0000240730.86237.b6 · Cited by 21

Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity

Yazıcı, D., Eser, H. Y., Kiyici, S. K., Sancak, S., Sezer, H., Uygur, M., & Yumuk, V. (2022) · Obesity Facts · doi:10.1159/000526808 · Cited by 26

Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life

Shchendrygina, A., Rakisheva, A., Giverts, I., Rustamova, Y., & Soloveva, A. E. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.05 · Cited by 23

Second line therapy: type 2 diabetic subjects failing on metformin GLP‐1/DPP‐IV inhibitors versus sulphonylurea/insulin: For GLP‐1/DPP‐IV inhibitors

Kumar, A. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2350 · Cited by 21

A Physiologic and Pharmacological Basis for Implementation of Incretin Hormones in the Treatment of Type 2 Diabetes Mellitus

Freeman, J. S. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0467 · Cited by 21

Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors

Bistola, V., Lambadiari, V., Dimitriadis, G., Ioannidis, I., Makrilakis, K., Tentolouris, N., Τσάπας, Α., & Parissis, J. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9674-3 · Cited by 21

Neonatal Exendin-4 Leads to Protection from Reperfusion Injury and Reduced Rates of Oxidative Phosphorylation in the Adult Rat Heart

Brown, S. B., Libonati, J. R., Selak, M. A., Shannon, R. P., & Simmons, R. A. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6242-z · Cited by 20

Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis

Chou, C., Chang, Y., Yang, J.-L., Wang, J., Lee, T.-E., Wang, R., & Hung, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-16101-1 · Cited by 20

Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies

Giblett, J. P., Axell, R. G., White, P. A., Clarke, S. J., McCormick, L., Read, P. A., Reinhold, J., Brown, A. J., O’Sullivan, M., West, N. E. J., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0416-3 · Cited by 20

Sitagliptin protects diabetic rats with acute myocardial infarction through induction of angiogenesis: role of IGF-1 and VEGF

Khodeer, D. M., Bilasy, S. E., Farag, N. E., Mehana, A. E., & El-Baz, A. A. (2019) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2018-0670 · Cited by 20

The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes

Kim, G. S., Park, J. H., & Won, J. C. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.2.106 · Cited by 20

Evaluation of Intragastric Vs Intraperitoneal Glucose Tolerance Tests in the Evaluation of Insulin Resistance in a Rodent Model of Burn Injury and Glucagon-Like Polypeptide-1 Treatment

Watada, S., Yu, Y., Fischman, A. J., Kurihara, T., Shen, C.-A., Tompkins, R. G., & Fagan, S. P. (2013) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e31828a8ede · Cited by 20

The GLP‐1 system as a therapeutic target

Edwards, M. C. B. (2005) · Annals of Medicine · doi:10.1080/07853890510037400 · Cited by 19

Effect of exenatide on the cardiac expression of adiponectin receptor 1 and NADPH oxidase subunits and heart function in streptozotocin-induced diabetic rats

Guo, Z., Qi, W., Yu, Y.-X., Du, S., Wu, J., & Liu, J. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-29 · Cited by 20

No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase‐4 inhibitors vs therapeutic alternatives

Gokhale, M., Buse, J. B., Funk, M. J., Lund, J. L., Pate, V., Simpson, R. J., & Stürmer‎, T. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12906 · Cited by 19

Effects of Liraglutide on Myocardial Function After Cardiac Surgery: A Secondary Analysis of the Randomised Controlled GLOBE Trial

Hulst, A., Visscher, M., Cherpanath, T., van de Wouw, L., Godfried, M., Thiel, B., Gerritse, B., Scohy, T., Bouwman, R. A., Willemsen, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030673 · Cited by 21

Therapeutic approaches to diabetic cardiomyopathy: Targeting the antioxidant pathway

Arad, M., Waldman, M., Abraham, N. G., & Hochhauser, E. (2020) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2020.106454 · Cited by 20

Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits hyperglycemia-induced apoptosis in myocytes by suppressing receptor for advanced glycation end products expression

Yi, B., Hu, X., Wen, Z., Zhang, T., & Cai, Y. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1873 · Cited by 19

Potential cardiovascular effects of incretin-based therapies

Deacon, C. F., & Marx, N. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.5 · Cited by 19

Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure

Nathanson, D., Frick, M., Ullman, B., & Nyström, T. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0116-2 · Cited by 19

Clinical translation of cardioprotective strategies

Hausenloy, D. J., & Yellon, D. M. (2008) · Basic Research in Cardiology · doi:10.1007/s00395-008-0736-x · Cited by 19

New therapies for type 2 diabetes based on glucagon-like peptide 1.

Salehi, M., & D’Alessio, D. A. (2006) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.73.4.382 · Cited by 19

Focus on Incretin-Based Therapies: Targeting the Core Defects of Type 2 Diabetes

Jellinger, P. S. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.01.2245 · Cited by 21

Identification of a prolonged action molecular GLP-1R agonist for the treatment of femoral defects

Wang, N., Liu, X., Shi, L., Liu, Y., Guo, S., Liu, W., Li, X., Meng, J., Ma, X., & Guo, Z. (2020) · Biomaterials Science · doi:10.1039/c9bm01426h · Cited by 18

A Glucagon-like Peptide 1 Analog Protects Mitochondria and Attenuates Hypoxia–Reoxygenation Injury in Cultured Cardiomyocytes

Kobara, M., Toba, H., & Nakata, T. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001218 · Cited by 19

Glucagon-like peptide-1 (7–36) but not (9–36) augments cardiac output during myocardial ischemia via a Frank–Starling mechanism

Goodwill, A. G., Tune, J. D., Noblet, J. N., Conteh, A. M., Sassoon, D., Casalini, E. D., & Mather, K. J. (2014) · Basic Research in Cardiology · doi:10.1007/s00395-014-0426-9 · Cited by 18

Harnessing the incretin system beyond glucose control: Potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes

Cariou, B. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.04.003 · Cited by 18

Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes

Tan, X., Cao, X., Zhou, M., Zou, P., & Hu, J. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1360274 · Cited by 18

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders

Wroge, J., & Williams, N. T. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016663218 · Cited by 17

Exendin-4 alleviates myocardial ischemia reperfusion injury by enhancing autophagy through promoting nuclear translocation of TFEB

He, W., Tong, G., Fan, H., Zhen, C., Zeng, L., Xue, L., Chen, J.-Y., Sun, Z., & He, P. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113469 · Cited by 17

Effects of Dipeptidyl-Peptidase 4 Inhibitor about Vascular Inflammation in a Metabolic Syndrome Model

Renna, N. F., Diez, E. R., & Miatello, R. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106563 · Cited by 17

Cardiovascular and hemodynamic effects of glucagon-like peptide-1

Goodwill, A. G., Mather, K. J., Conteh, A. M., Sassoon, D., Noblet, J. N., & Tune, J. D. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9290-z · Cited by 17

Multifactorial intervention in Type 2 diabetes: The promise of incretin-based therapies

Giorgino, F., Leonardini, A., Natalicchio, A., & Laviola, L. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03346698 · Cited by 17

Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials

Huang, M., Wei, R., Wang, Y., Su, T.-Y., Li, Q., Yang, X., & Chen, X. (2017) · Annals of Medicine · doi:10.1080/07853890.2017.1306653 · Cited by 35

GLP-1 Infusions in the setting of Acute Myocardial Infarction Improve Myocardial Function and Reduce Morbidity and Mortality

Bush, G. J. (2013)

Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease

Read, P. A., Khan, F. Z., & Dutka, D. P. (2011) · Heart · doi:10.1136/hrt.2010.219345 · Cited by 114

Role of glucagon-like peptide-1 agonist in patients undergoing percutaneous coronary intervention or coronary artery bypass grafting: A meta-analysis

Ogbu, I. R., Ngwudike, C., Lal, K., Danielian, A., & Daoud, S. N. (2021) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2021.100063 · Cited by 4

Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus

McCormick, L. M., Heck, P. M., Ring, L. S., Kydd, A. C., Clarke, S. J., Hoole, S. P., & Dutka, D. P. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0259-3 · Cited by 23